More than 8% of all prescriptions in June 2026 were for GLP-1 RAs, increasing slightly (+5.6%) since March 2026. Tirzepatide remained the leading anti-obesity medication (AOM) and anti-diabetic medication (ADM) by prescription volume and showed the largest increase in total prescribing from March to June 2026. Following FDA approval in April 2026, orforglipron (Foundayo pill) prescribing increased by 0.05 percentage points.
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules